PP1131

AXP000228.1 · Phage therapy

Platform
phage cocktail (12 phages)
Originator
Pherecydes Pharma
Sponsor
Phaxiam Therapeutics

Names

NameTypeSource
PP1131preferred name, codecurator, paper

Virus

Role
Phage
Family
Caudoviricetes
Virus
Pseudomonas aeruginosa bacteriophage (12-phage cocktail)
Replication
replicating
Route
topical
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 30292481Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.The Lancet. Infectious diseases2019name in abstract: PP1131

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42617616Non-canonical phage-bacterium interactions during topical phage therapy in the PhagoBurn clinical trial: a retrospective, observational, reverse translational study.The Lancet. Microbe2026name in abstract: PP1131

Notes

Cocktail of 12 natural lytic anti-Pseudomonas aeruginosa phages, applied to burn wounds in the PhagoBurn trial NCT02116010 (Jault 2019, Lancet Infect Dis). PhagoBurn also had an anti-E. coli arm whose product name is not given in the sources seen, so no program was created for it. Pherecydes Pharma merged with Erytech in 2023 to form Phaxiam Therapeutics.

How to cite

PP1131 (AXP000228.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000228.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.